We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.22 | -0.15% | 149.70 | 149.89 | 147.82 | 149.89 | 6,532,721 | 00:38:06 |
From May 2021 to May 2024
By Matt Grossman
Johnson & Johnson's booster vaccine for Covid-19 was 85% effective against hospitalization in a study conducted in South Africa after the Omicron variant became dominant, the company said Thursday.
The study was conducted among healthcare workers in South Africa who had received a single shot of the Johnson & Johnson vaccine as their primary vaccination. Vaccine efficacy against hospitalization increased to 85% after a booster shot, even after Omicron became the most widespread strain in the region, New Brunswick, N.J.-based Johnson & Johnson said.
A separate study of vaccine regimens found that the company's booster vaccine increased the immune response when administered to patients who had received a different primary vaccine, Johnson & Johnson said. The Johnson & Johnson booster generated a 41-fold increase in neutralizing antibody responses and a 5-fold increase in CD8+ T-cells to Omicron by four weeks following the boost, the company said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
December 30, 2021 06:58 ET (11:58 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
